Bimetinib/Bemetinib 2025 medical insurance price

Binimetinib/Binimetinib is a kinase inhibitor targeting the MEK signaling pathway. It is mainly used to treat melanoma and non-small cell lung cancer with specific gene mutations. This drug, used in combination with canafenib (Encorafenib), provides a new treatment option for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and for patients with metastatic non-small cell lung cancer with BRAF V600E mutations.

Although bimetinib has been used to some extent in the international market, its original drug has not yet been marketed in China, and therefore has not been included in my country's medical insurance system. For patients, this means they need to pay for the drug out-of-pocket when receiving treatment, thereby increasing their medical burden. Due to the high import cost of bimetinib, its pricing is generally more expensive in overseas markets.

In overseas markets, the price of bimetinib is relatively high. The common packaging specifications of the European version of Bimetinib are 15mg*84 tablets and 15mg*168 tablets. The price per box is about 20,000 yuan (the specific price may fluctuate due to exchange rate changes). Although expensive, bimetinib's remarkable efficacy in the treatment of melanoma and non-small cell lung cancer has brought new hope to many patients.

In addition, the first generic drug of bimetinib has been launched in overseas markets. These generic drugs contain roughly the same ingredients as the brand-name drugs, but are relatively less expensive. For example, the price of a box of 15mg*180 tablets of bimetinib generics produced by Lucius Pharmaceuticals in Laos may be around RMB 6,000 (also affected by exchange rates, the price may fluctuate). However, when choosing generic drugs, patients should carefully consider their quality and safety issues, as well as the legality of the purchasing channels.

Reference materials:https://www.drugs.com/history/mektovi.html